Piperazine-Based Co(III), Ni(II), Cu(II), and Zn(II) Carbodithioate Complexes as Potential Anticancer Agent

Area of Science:

• Coordination Chemistry
• Medicinal Chemistry
• Cancer Research

Background:

• Development of cost-effective anticancer drugs with minimal side effects is crucial.
• Piperazine-containing compounds are a known class of anticancer agents.
• This study explores novel metal complexes derived from a piperazine-based ligand.

Purpose of the Study:

• To synthesize and characterize novel metal complexes of potassium 4-(ethoxycarbonyl)piperazine-1-carbodithioate [pecpcdt].
• To evaluate the in vitro anticancer activity of these complexes against Dalton's lymphoma (DL) cells.
• To investigate the mechanism of action for the most potent complex.

Main Methods:

• Synthesis and characterization of ligand [pecpcdt] and its metal complexes (Co, Ni, Cu, Zn) using spectroscopic methods and X-ray crystallography.
• In vitro anticancer activity assessment against DL cells using biochemical assays.
• Mechanism of action studies for the cobalt(III) complex involving mitochondrial assays.

Main Results:

• Synthesized and characterized four metal complexes: [Co(ecpcdt)3] (1), [Ni(ecpcdt)2] (2), [Cu(ecpcdt)2] (3), and [Zn(ecpcdt)2] (4).
• Complexes exhibited varying degrees of anticancer activity, with [Co(ecpcdt)3] (1) showing superior cytotoxicity compared to cisplatin.
• The cobalt(III) complex induces tumor cell death via mitochondrial-dependent apoptosis, evidenced by reduced mitochondrial membrane potential and increased ROS production.
• Normal splenocytes showed minimal impact from the cobalt(III) complex treatment.

Conclusions:

• The synthesized piperazine-based metal complexes possess significant anticancer potential.
• [Co(ecpcdt)3] (1) is a promising candidate for further anticancer drug development due to its high efficacy and targeted mechanism.
• The study highlights the role of mitochondrial pathways in the anticancer action of these novel metallodrugs.